Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the pyrazolo[3,4-d]pyrimidine family and contains a phenolic group. It has been investigated primarily as a research tool and chemical building block. In biological studies, it has shown activity as an inhibitor of phosphatidylinositol 4,5-bisphosphate 3‑kinase catalytic subunit gamma isoform (PIK3CG) and proto-oncogene tyrosine-protein kinase Src. These targets are relevant in cancer biology and cell signaling pathways. The compound is considered experimental with no approved therapeutic indications but is used in medicinal chemistry for the development of new agents targeting these kinases[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[4-amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenol.